Brick by brick: metabolism and tumor cell growth

Current Opinion in Genetics and Development

Volumn 18, Issue 1, 2008, Pages 54-61

  DeBerardinis, Ralph J ^a,b,c   Sayed, Nabil ^a,b   Ditsworth, Dara ^a   Thompson, Craig B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUTAMINE; LIPID;

AMINO ACID SYNTHESIS; BIOENERGY; CANCER GROWTH; CELL METABOLISM; CELL PROLIFERATION; CITRIC ACID CYCLE; FATTY ACID SYNTHESIS; GLYCOLYSIS; HUMAN; METABOLIC REGULATION; NONHUMAN; NUCLEOTIDE METABOLISM; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW;

CELL PROLIFERATION; FATTY ACIDS; GLUTAMINE; GLYCOLYSIS; HUMANS; LIPIDS; MODELS, BIOLOGICAL; NEOPLASMS; RIBOSEMONOPHOSPHATES;

EID: 43749083041     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2008.02.003     Document Type: Review

References (63)

1. Warburg O. Uber den Stoffwechsel der Carcinomzelle. Klin Wochenschr Berl 4 (1925) 534-536
2. Warburg O. On the origin of cancer cells. Science 123 (1956) 309-314
3. Kim J.W., and Dang C.V. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 66 (2006) 8927-8930
4. Wang T., Marquardt C., and Foker J. Aerobic glycolysis during lymphocyte proliferation. Nature 261 (1976) 702-705
5. Bauer D.E., Harris M.H., Plas D.R., Lum J.J., Hammerman P.S., Rathmell J.C., Riley J.L., and Thompson C.B. Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand. FASEB J 18 (2004) 1303-1305
6. Ramanathan A., Wang C., and Schreiber S.L. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci U S A 102 (2005) 5992-5997. Using serial transduction of primary human fibroblasts with telomerase, SV40 large T and small T antigens, and oncogenic H-ras, the authors demonstrated that progressive cellular transformation led to increased reliance on glycolysis for energy production.
7. Brand K. Glutamine and glucose metabolism during thymocyte proliferation. Pathways of glutamine and glutamate metabolism. Biochem J 228 (1985) 353-361
8. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., and Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7 (2008) 11-20
9. Dang C.V., Lewis B.C., Dolde C., Dang G., and Shim H. Oncogenes in tumor metabolism, tumorigenesis, and apoptosis. J Bioenerg Biomembr 29 (1997) 345-354
10. Rashid A., Pizer E.S., Moga M., Milgraum L.Z., Zahurak M., Pasternack G.R., Kuhajda F.P., and Hamilton S.R. Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol 150 (1997) 201-208
11. Bensaad K., Tsuruta A., Selak M.A., Vidal M.N., Nakano K., Bartrons R., Gottlieb E., and Vousden K.H. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126 (2006) 107-120. The authors identified a p53 target gene, TIGAR, which lowers cellular fructose 2,6-bisphosphate levels, resulting in decreased glycolysis and intracellular reactive oxygen species after exposure to DNA damaging agents. They proposed that TIGAR links p53 activation to cell survival in the face of genotoxic stress via its influence on glucose metabolism.
12. Bensaad K., and Vousden K.H. p53: new roles in metabolism. Trends Cell Biol 17 (2007) 286-291
13. Kondoh H., Lleonart M.E., Gil J., Wang J., Degan P., Peters G., Martinez D., Carnero A., and Beach D. Glycolytic enzymes can modulate cellular life span. Cancer Res 65 (2005) 177-185
14. Matoba S., Kang J.G., Patino W.D., Wragg A., Boehm M., Gavrilova O., Hurley P.J., Bunz F., and Hwang P.M. p53 regulates mitochondrial respiration. Science 312 (2006) 1650-1653. SCO2 encodes an assembly factor for cytochrome c-oxidase (complex IV of the electron transport chain). The authors determined that SCO2 is a p53 target, and that deletion of p53 results in increased aerobic glycolysis that can be reversed by re-expressing SCO2. Thus, p53 deletion was sufficient to induce the Warburg effect.
15. Mazurek S., Boschek C.B., Hugo F., and Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 15 (2005) 300-308
16. Netzker R., Greiner E., Eigenbrodt E., Noguchi T., Tanaka T., and Brand K. Cell cycle-associated expression of M2-type isozyme of pyruvate kinase in proliferating rat thymocytes. J Biol Chem 267 (1992) 6421-6424
17. Altenberg B., and Greulich K.O. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84 (2004) 1014-1020
18. Boros L.G., Puigjaner J., Cascante M., Lee W.N., Brandes J.L., Bassilian S., Yusuf F.I., Williams R.D., Muscarella P., Melvin W.S., et al. Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res 57 (1997) 4242-4248
19. Forbes N.S., Meadows A.L., Clark D.S., and Blanch H.W. Estradiol stimulates the biosynthetic pathways of breast cancer cells: detection by metabolic flux analysis. Metab Eng 8 (2006) 639-652. The authors studied the impact of estradiol stimulation on the metabolism of MCF7 breast cancer cells, using a flux analysis algorithm that allowed them to measure some 30 individual metabolic activities. Estradiol, which induced cell proliferation, concomitantly enhanced glycolysis, the pentose phosphate pathway, glutaminolysis and other activities. The authors concluded that estradiol-stimulated cells consumed glutamine largely to support biosynthesis rather than bioenergetics.
20. Boros L.G., Cascante M., and Lee W.N. Metabolic profiling of cell growth and death in cancer: applications in drug discovery. Drug Discov Today 7 (2002) 364-372
21. Cocco P., Todde P., Fornera S., Manca M.B., Manca P., and Sias A.R. Mortality in a cohort of men expressing the glucose-6-phosphate dehydrogenase deficiency. Blood 91 (1998) 706-709
22. Cocco P., Dessi S., Avataneo G., Picchiri G., and Heinemann E. Glucose-6-phosphate dehydrogenase deficiency and cancer in a Sardinian male population: a case-control study. Carcinogenesis 10 (1989) 813-816
23. Comin-Anduix B., Boren J., Martinez S., Moro C., Centelles J.J., Trebukhina R., Petushok N., Lee W.N., Boros L.G., and Cascante M. The effect of thiamine supplementation on tumour proliferation. A metabolic control analysis study. Eur J Biochem 268 (2001) 4177-4182
24. Langbein S., Zerilli M., Zur Hausen A., Staiger W., Rensch-Boschert K., Lukan N., Popa J., Ternullo M.P., Steidler A., Weiss C., et al. Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer 94 (2006) 578-585. Using immunohistochemistry on more than 1000 carcinomas covering 16 epithelial tumor entities, the authors detected enhanced TKTL1 expression in more than 80% of the samples. In invasive colon and urothelial carcinomas, TKTL1 staining correlated with poor patient outcome.
25. Krockenberger M., Honig A., Rieger L., Coy J.F., Sutterlin M., Kapp M., Horn E., Dietl J., and Kammerer U. Transketolase-like 1 expression correlates with subtypes of ovarian cancer and the presence of distant metastases. Int J Gynecol Cancer 17 (2007) 101-106. The authors used immunohistochemistry to study TKTL1 expression in a variety of ovarian adenocarcinomas and in normal ovaries. Serous papillary tumors had significantly higher TKTL1 expression than other ovarian carcinomas or normal tissues. Among the 20 serous papillary tumors studied, high TKTL1 expression correlated with poor prognostic parameters, including clinical staging and histopathological grading.
26. Stryer L., Berg J.M., and Tymoczko J.L. The calvin cycle and the pentose phosphate pathway. In: Stryer L., Berg J.M., and Tymoczko J.L. (Eds). Biochemistry. 5th ed. (2002), W.H. Freeman and Company 568-570
27. Swinnen J.V., Brusselmans K., and Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 9 (2006) 358-365
28. Kannan R., Lyon I., and Baker N. Dietary control of lipogenesis in vivo in host tissues and tumors of mice bearing Ehrlich ascites carcinoma. Cancer Res 40 (1980) 4606-4611
29. Ookhtens M., Kannan R., Lyon I., and Baker N. Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am J Physiol 247 (1984) R146-R153
30. Kuhajda F.P., Jenner K., Wood F.D., Hennigar R.A., Jacobs L.B., Dick J.D., and Pasternack G.R. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A 91 (1994) 6379-6383
31. Pizer E.S., Wood F.D., Heine H.S., Romantsev F.E., Pasternack G.R., and Kuhajda F.P. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 56 (1996) 1189-1193
32. Hatzivassiliou G., Zhao F., Bauer D.E., Andreadis C., Shaw A.N., Dhanak D., Hingorani S.R., Tuveson D.A., and Thompson C.B. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8 (2005) 311-321
33. Brusselmans K., De Schrijver E., Verhoeven G., and Swinnen J.V. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 65 (2005) 6719-6725
34. Chajes V., Cambot M., Moreau K., Lenoir G.M., and Joulin V. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res 66 (2006) 5287-5294
35. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
36. Samuels Y., and Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18 (2006) 77-82
37. Porstmann T., Griffiths B., Chung Y.L., Delpuech O., Griffiths J.R., Downward J., and Schulze A. PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 24 (2005) 6465-6481
38. Chang Y., Wang J., Lu X., Thewke D.P., and Mason R.J. KGF induces lipogenic genes through a PI3K and JNK/SREBP-1 pathway in H292 cells. J Lipid Res 46 (2005) 2624-2635
39. Edinger A.L., and Thompson C.B. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 13 (2002) 2276-2288
40. Wieman H.L., Wofford J.A., and Rathmell J.C. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell 18 (2007) 1437-1446
41. Buzzai M., Bauer D.E., Jones R.G., Deberardinis R.J., Hatzivassiliou G., Elstrom R.L., and Thompson C.B. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 24 (2005) 4165-4173
42. DeBerardinis R.J., Lum J.J., and Thompson C.B. Phosphatidylinositol 3-kinase-dependent modulation of carnitine palmitoyltransferase 1A expression regulates lipid metabolism during hematopoietic cell growth. J Biol Chem 281 (2006) 37372-37380. Carnitine palmitoyltransferase-1A (CPT1A), the rate-limiting enzyme for β-oxidation of fatty acids, can be allosterically inhibited by malonyl-CoA, and this mechanism regulates β-oxidation activity in muscle and liver. In this study, the authors demonstrated that stimulation of PI3K/Akt suppressed expression of CPT1A, reducing its abundance during cell growth and proliferation. CPT1A suppression was necessary to allow cells to reduce their β-oxidation rate and to achieve maximal rates of lipid synthesis and proliferation.
43. Lum J.J., Bui T., Gruber M., Gordan J.D., DeBerardinis R.J., Covello K.L., Simon M.C., and Thompson C.B. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev 21 (2007) 1037-1049. The authors determined that growth factor signaling permitted cells to express HIF-1α, and that HIF-1α controlled the fate of glucose carbon during normoxia as well as hypoxia. Expression of HIF-1α allowed cells to convert a high fraction of glucose carbon into lactate but suppressed fatty acid synthesis and cell growth. Inhibiting HIF-1α expression with RNA interference increased lipogenesis and cell growth.
44. Chang L.O., and Morris H.P. Enzymatic and immunological studies on pyruvate carboxylase in livers and liver tumors. Cancer Res 33 (1973) 2034-2041
45. Hammond K.D., and Balinsky D. Activities of key gluconeogenic enzymes and glycogen synthase in rat and human livers, hepatomas, and hepatoma cell cultures. Cancer Res 38 (1978) 1317-1322
46. Brand A., Engelmann J., and Leibfritz D. A 13C NMR study on fluxes into the TCA cycle of neuronal and glial tumor cell lines and primary cells. Biochimie 74 (1992) 941-948
47. 13C-labeled glucose and glutamine in order to study metabolic activities during cell proliferation. The cells had a functional TCA cycle characterized by a high rate of anaplerosis, for which almost all the carbon was derived from glutamine. The authors also determined that glutaminolysis could provide more than enough NADPH needed for fatty acid synthesis. The pathways of glutamine utilization resulted in a loss of more than half of glutamine's carbon and nitrogen from the cell.
48. Amemiya-Kudo M., Shimano H., Hasty A.H., Yahagi N., Yoshikawa T., Matsuzaka T., Okazaki H., Tamura Y., Iizuka Y., Ohashi K., et al. Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes. J Lipid Res 43 (2002) 1220-1235
49. Eagle H., Oyama V.I., Levy M., Horton C.L., and Fleischman R. The growth response of mammalian cells in tissue culture to l-glutamine and l-glutamic acid. J Biol Chem 218 (1956) 607-616
50. Reitzer L.J., Wice B.M., and Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem 254 (1979) 2669-2676
51. Turner A., and McGivan J.D. Glutaminase isoform expression in cell lines derived from human colorectal adenomas and carcinomas. Biochem J 370 (2003) 403-408
52. Perez-Gomez C., Campos-Sandoval J.A., Alonso F.J., Segura J.A., Manzanares E., Ruiz-Sanchez P., Gonzalez M.E., Marquez J., and Mates J.M. Co-expression of glutaminase K and L isoenzymes in human tumour cells. Biochem J 386 (2005) 535-542
53. Matsuno T., and Hirai H. Glutamine synthetase and glutaminase activities in various hepatoma cells. Biochem Int 19 (1989) 219-225
54. Matsuno T., and Goto I. Glutaminase and glutamine synthetase activities in human cirrhotic liver and hepatocellular carcinoma. Cancer Res 52 (1992) 1192-1194
55. Aledo J.C., Segura J.A., Medina M.A., Alonso F.J., Nunez de Castro I., and Marquez J. Phosphate-activated glutaminase expression during tumor development. FEBS Lett 341 (1994) 39-42
56. Ahluwalia G.S., Grem J.L., Hao Z., and Cooney D.A. Metabolism and action of amino acid analog anti-cancer agents. Pharmacol Ther 46 (1990) 243-271
57. Lobo C., Ruiz-Bellido M.A., Aledo J.C., Marquez J., Nunez De Castro I., and Alonso F.J. Inhibition of glutaminase expression by antisense mRNA decreases growth and tumourigenicity of tumour cells. Biochem J 348 Pt 2 (2000) 257-261
58. Elgadi K.M., Meguid R.A., Qian M., Souba W.W., and Abcouwer S.F. Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiol Genomics 1 (1999) 51-62
59. Porter L.D., Ibrahim H., Taylor L., and Curthoys N.P. Complexity and species variation of the kidney-type glutaminase gene. Physiol Genomics 9 (2002) 157-166
60. Portais J.C., Voisin P., Merle M., and Canioni P. Glucose and glutamine metabolism in C6 glioma cells studied by carbon 13 NMR. Biochimie 78 (1996) 155-164
61. Yuneva M., Zamboni N., Oefner P., Sachidanandam R., and Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 178 (2007) 93-105
62. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., Fleming M.D., Schreiber S.L., and Cantley L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumor growth. Nature 452 (2008) 230-233. The authors manipulated the expression of the pyruvate kinase M2 and M1 isoforms in human tumor cells and showed that expression of the M1 isoform was sufficient to reduce lactate production and increase cellular respiration. These cells also exhibited delayed tumor growth compared to M2-expressing cells in a xenograft model.
63. Christofk H.R., Vander Heiden M.G., Wu N., Asara J.M., and Cantley L.C. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452 (2008) 181-186